{"title":"Injectable Bone Cements: A Generational Framework for Bioactivity, Porosity, and Mechanobiological Design at the Nanoscale","authors":"Frank Fei, Yogambha Ramaswamy, Young Jung No","doi":"10.1002/anbr.202500311","DOIUrl":null,"url":null,"abstract":"<p>Injectable bone cements (IBCs) are widely used in orthopaedic and craniofacial applications due to their minimally invasive delivery and ability to provide early mechanical stabilisation. Despite substantial progress, clinical translation remains limited by persistent challenges, including insufficient bioactivity, poor control of porosity and interconnectivity, and the limited integration of mechanobiological design principles. Additional constraints arise from the need to balance injectability, setting behaviour, and mechanical performance. Most existing reviews categorise IBCs by material composition, often overlooking important conceptual advances in functionality. Here, we propose a generation-based classification framework that captures successive shifts in injectable cement design, from first-generation bioinert structural fillers to second-generation resorbable, osteoconductive systems, to third-generation bioactivity-enhanced doped and composite formulations, and finally to fourth-generation cements incorporating hierarchical macro- and nanoscale architectures. This latest generation integrates nanomaterials and engineered pore structures to regulate cell–matrix interactions, mechanotransduction, and tissue regeneration. Across each generation, we critically examine the interdependence of biological, mechanical, and rheological properties, highlighting how architectural and mechanical cues modulate cellular responses. By synthesising advances in materials science and mechanobiology, this review outlines emerging strategies for the design of regenerative, mechanobiologically informed IBCs.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 8","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500311","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202500311","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Injectable bone cements (IBCs) are widely used in orthopaedic and craniofacial applications due to their minimally invasive delivery and ability to provide early mechanical stabilisation. Despite substantial progress, clinical translation remains limited by persistent challenges, including insufficient bioactivity, poor control of porosity and interconnectivity, and the limited integration of mechanobiological design principles. Additional constraints arise from the need to balance injectability, setting behaviour, and mechanical performance. Most existing reviews categorise IBCs by material composition, often overlooking important conceptual advances in functionality. Here, we propose a generation-based classification framework that captures successive shifts in injectable cement design, from first-generation bioinert structural fillers to second-generation resorbable, osteoconductive systems, to third-generation bioactivity-enhanced doped and composite formulations, and finally to fourth-generation cements incorporating hierarchical macro- and nanoscale architectures. This latest generation integrates nanomaterials and engineered pore structures to regulate cell–matrix interactions, mechanotransduction, and tissue regeneration. Across each generation, we critically examine the interdependence of biological, mechanical, and rheological properties, highlighting how architectural and mechanical cues modulate cellular responses. By synthesising advances in materials science and mechanobiology, this review outlines emerging strategies for the design of regenerative, mechanobiologically informed IBCs.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.